News & Resources
BGF investment fund's Paul Stevens: IXICO has “market leading position" & “impressive commercial traction”
The comments were made during the following Q&A session with Paul Stevens from BGF’s investment fund, who focuses on identifying opportunities among AIM-listed companies: 1. Can you provide some background on BGF and the sectors/types of companies you invest in?BGF was set up in 2011 to help support small growing companies in the UK.
Clinical Trials on Alzheimer’s Disease (CTAD) Poster 2019
Classifying cognitively healthy subjects from mild cognitive impaired and Alzheimer's disease patients using Tau-PET: The role of spatial resolution and PET pre-processing
Clinical Trials on Alzheimer’s Disease (CTAD) Poster 2019
A fully automatic pipeline for estimation of regional brain volume change using Jacobian integration
Clinical Trials on Alzheimer’s Disease (CTAD) Poster 2019
A pipeline for automated diffusion MRI analysis: overview and application to the study of Alzheimer’s Disease
Huntington Study Group (HSG) Annual Meeting Poster 2019
A Fully Automatic Pipeline for Estimation of Putamen and Caudate Volume
Investors chronicle: 'IXICO upgrades guidance again'
Published on investors chronicle: 15th October Author: Simon Thompson The world’s largest biopharmaceutical companies are investing huge sums of money in the field of neurology to target therapies for diseases affecting the central nervous system including Huntington’s, Alzheimer’s and Parkinson’s disease.
Spinocerebellar Ataxias (SCA) Global Conference 2019 Poster
Development of a fully automated method for MRI volumetry in ataxia
113-120 of 180 results